Format

Send to

Choose Destination
J Pediatr Surg. 1997 Feb;32(2):287-93.

TNP-470 antiangiogenic therapy for advanced murine neuroblastoma.

Author information

1
Division of Pediatric Surgery, Children's Hospital Research Foundation, Children's Hospital Medical Center, Cincinnati, OH 45299, USA.

Abstract

The finding that angiogenesis plays an important role in the progression and metastasis of malignant tumors has led to the development of several antiangiogenic drugs. The authors report here an examination of the effect of the antiangiogenic agent TNP-470 on the growth, metastases, and survival of two differing murine neuroblastoma cell lines, TBJ and C1300. We found that TNP-470 significantly reduced primary tumor volumes in mice injected with either cell line. In addition, antiangiogenic therapy significantly reduced the size of axillary lymph node metastases in both groups as well as decreased the size of liver metastases in mice receiving TBJ neuroblastoma. TNP-470 treatment also improved animal survival. These data suggest that antiangiogenic therapy retards the growth of primary and metastatic murine neuroblastoma. We speculate that antiangiogenic therapy may be a useful therapeutic modality in the treatment of advanced neuroblastoma once side effects and appropriate dosage requirements are determined.

PMID:
9044139
DOI:
10.1016/s0022-3468(97)90196-2
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center